Adalimumab medium-term dosing strategy in moderate-to-severe hidradenitis suppurativa: integrated results from the phase III randomized placebo-controlled PIONEER trials

MLA

Jemec, G. B. E.(Gregor), et al. Adalimumab Medium-Term Dosing Strategy in Moderate-to-Severe Hidradenitis Suppurativa: Integrated Results from the Phase III Randomized Placebo-Controlled PIONEER Trials. 2019. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1121177244&authtype=sso&custid=ns315887.

APA

Jemec, G. B. E. (Gregor), Okun, M. (Martin), Forman, S. B. (S. B. ., Gulliver, W. P. (Wayne P. ., Prens, E. P. (Errol), Mrowietz, U. (Ulrich), Armstrong, A. W. (A. W. ., Geng, Z. (Z. ., Gu, Y. (Yihua), Williams, D. A. (D. A. ., Teixeira, H. D. (H. D. ., & Kimball, A. B. (Alexa). (2019). Adalimumab medium-term dosing strategy in moderate-to-severe hidradenitis suppurativa: integrated results from the phase III randomized placebo-controlled PIONEER trials.

Chicago

Jemec, G.B.E. (Gregor), M. (Martin) Okun, S.B. (S. B.) Forman, W.P. (Wayne P.) Gulliver, E.P. (Errol) Prens, U. (Ulrich) Mrowietz, A.W. (A. W.) Armstrong, et al. 2019. “Adalimumab Medium-Term Dosing Strategy in Moderate-to-Severe Hidradenitis Suppurativa: Integrated Results from the Phase III Randomized Placebo-Controlled PIONEER Trials.” http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1121177244&authtype=sso&custid=ns315887.